ArticlePloS one2011
IL-27 imparts immunoregulatory function to human NK cell subsets.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 54 citations in OpenAlex.
- Viral load-driven systemic immune exhaustion is an enabler of antibody breadth in HIV infection.bioRxiv : the preprint server for biology · 2026Article
- An updated advancement of bifunctional IL-27 in inflammatory autoimmune diseases.Frontiers in immunology · 2024Review
- CD56bright CD16- natural killer cells as an important regulatory mechanism in chronic graft-Haematologica · 2023Article
- Regulatory NK cells in autoimmune disease.Iranian journal of basic medical sciences · 2023Review
- Implications of a 'Third Signal' in NK Cells.Cells · 2021Review
- The Role of Natural Killer Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection.Frontiers in immunology · 2021Review
- The contribution from interleukin-27 towards rheumatoid inflammation: insights from gene expression.Genes and immunity · 2020Article
- CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis.Journal of clinical medicine · 2020Review
- Vitamin D and connective tissue diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- Review
- Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.Frontiers in immunology · 2020Review
- Review
- Resolution of inflammation during multiple sclerosis.Seminars in immunopathology · 2019Review
- IL-27 enhances IL-15/IL-18-mediated activation of human natural killer cells.Journal for immunotherapy of cancer · 2019Article
- IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection.Scientific reports · 2019Article
- Natural Killer Cells: Development, Maturation, and Clinical Utilization.Frontiers in immunology · 2018Review
- IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression.Scientific reports · 2017Article
- Altered populations of natural killer cells, cytotoxic T lymphocytes, and regulatory T cells in major depressive disorder: Association with sleep disturbance.Brain, behavior, and immunity · 2017Article
- Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-27 (IL-27) is a cytokine with multiple roles in regulating the immune response, but its effect on human CD56(bright) and CD56(dim) NK cell subsets is unknown. NK cell subsets interact with other components of the immune system, leading to cytotoxicity or immunoregulation depending on stimulating factors. We found that IL-27 treatment results in increased IL-10 and IFN-γ expression, increased viability and decreased proliferation in both CD56(bright) and CD56(dim) NK cell subsets. More importantly, IL-27 treatment imparts regulatory activity to CD56(bright) NK cells, which mediates its suppressive function on T cells in a contact-dependent manner. There is growing evidence that CD56(bright) NK cell-mediated immunoregulation plays an important role in the control of autoimmunity. Thus, understanding the role of IL-27 in NK cell function has important implications for treatment of autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.